GE HealthCare in the news

GE HealthCare is scheduled to release its results on October 28, followed by a live call.

GE HealthCare will acquire SOFIE Biosciences for $945 million to bolster its U.S. PET radiopharmaceutical manufacturing and distribution, including a Phase III radiotracer.

GE HealthCare has appointed Rodolphe Katra, formerly of Medtronic, as its global chief AI officer to advance its AI strategy and connect devices, software, and data.

GE HealthCare will acquire SOFIE Biosciences for $945 million to expand its footprint in the U.S. PET radiopharmaceutical supply chain.

GE HealthCare Technologies is acquiring Sofie Biosciences for $945 million to expand its medical technology solutions.

GE HealthCare will acquire Sofie Biosciences for $945 million to expand its radiopharmaceutical distribution network and enter new high-growth radiopharma markets.

GE HealthCare is set to acquire SOFIE Biosciences for $945 million, aiming to expand its U.S. PET radiopharmaceutical manufacturing and distribution capabilities and strengthen its position in the radiopharmaceutical market.

GE HealthCare will acquire Sofie Biosciences for $945 million to strengthen its radiopharmaceuticals market position by gaining US manufacturing, distribution for PET products, and US rights to the FAPI-74 radiotracer.

GE HealthCare will acquire Sofie Biosciences for $945 million, a deal that highlights market dynamics in medical technology.

GE HealthCare will acquire Sofie Biosciences for $945 million to enhance its radiopharmaceutical supply chain, expand manufacturing capabilities, and gain control over a pan-cancer PET radiotracer.

GE HealthCare is set to acquire Sofie Biosciences for $945 million to expand its radiopharmaceutical manufacturing capabilities and pipeline, including FAPI-74.

Citi lowered GE HealthCare's price target to $71 from $75 while maintaining a Neutral rating.

GE HealthCare paid $945 million to enhance its imaging drug business.

GE HealthCare's stock increased by 2.26% to $65.74 on Monday, outperforming the S&P 500 and Dow Jones Industrial Average.

GE HealthCare will acquire Sofie Biosciences for $945 million to enhance its radiopharmaceutical manufacturing and distribution capabilities in the U.S.

Philips, GE HealthCare, and Siemens Healthineers are being sued by MR Access Inc. for infringing MRI technology patents.

GE HealthCare increased its quarterly dividend to $0.04 per share while reporting mixed Q2 2026 results, showing growth in imaging and diagnostics but a decline in Patient Care Solutions, and analysts maintain a Moderate Buy rating.

GE HealthCare, Danaher, AstraZeneca, Daiichi Sankyo, Fresenius Medical Care, and BCG all made significant announcements this week in the healthcare sector, ranging from executive appointments and drug recommendations to new facility developments and market analyses.

GE HealthCare is under investigation for securities fraud after poor Q1 2026 results, a lowered financial outlook, and the resignation of its CFO.

A law firm is investigating GE HealthCare for securities fraud after the company reported reduced earnings and guidance due to a supplier recall, leading to a stock price drop and the CFO's resignation.